Silvercrest Asset Management’s Exagen XGN Stock Holding History
Bought
Maintained
Sold
Other funds holding XGN
WC
VCM
NCNMGF
KCM
FCM
RI
MBAM
Silvercrest Asset Management's XGN Position: Q1 2026 in Review
Silvercrest Asset Management reduced its Exagen (XGN) stake by 10% in Q1 2026, selling an estimated $232K and leaving 537,870 shares worth $1.61M. The position accounts for 0.01% of the portfolio, ranked #550.
Silvercrest Asset Management first reported a position in XGN in Q1 2021 and has held it in 21 quarters since. The position peaked at $6.97M in Q3 2021. 61 funds tracked by Wall St. Rank hold XGN as of Q1 2026.
- Silvercrest Asset Management held 537,870 shares of Exagen worth $1.61M as of Q1 2026.
- Silvercrest Asset Management sold 60,050 Exagen shares in Q1 2026, an estimated $232K.
- Exagen made up 0.01% of Silvercrest Asset Management's portfolio in Q1 2026, its #550 holding.
- Silvercrest Asset Management first reported a position in Exagen in Q1 2021 and has held it in 21 quarters since.
- Silvercrest Asset Management's Exagen position peaked at $6.97M in Q3 2021.
- 61 funds tracked by Wall St. Rank held Exagen as of Q1 2026.
Based on Silvercrest Asset Management's 13F filing for Q1 2026, filed 15 May 2026.